AVR

1.11%

$11.55 anteris technologies ltd

2:1000000 million chance of getting brain damage from Herpes, page-68

First 68 Last

Share
Profile

Follow
redant

3,160 Posts.

249

23/06/15

08:17

Post #: 15511691
Share

Originally posted by trythree ↑

The main point I was trying to make to impartial readers was that the market for herpes vaccine is very difficult to predict with any certainty, but that it was definitely less than any figure quoted on these boards by a long mile.

Comments such as more people in USA have herpes than the entire population of Australia are pure example of this.

The broadly agreed knowns go like this; around 50% of people with HSV-2 are unaware that they have it and it has zero impact on their life what so ever.
Of the other 50% a majority will see signs of shedding and will either disappear or they will take a pill, use some cream and the signs will never appear again and be forgotten.
This leaves a very small amount of people who have recurrent signs, use condoms and or other preventative measures and learn to live with it. This would be the target market and you would think most of the people in this category would be interested in taking the vaccine. This is a very small percentage of the numbers bounced around here.

Few other things to address:

Nobody is going to be rolling out Vaccine's for herpes in schools, or going to to the doctors to get an injection 'just in case', there are bigger day to day problems out there for people to preoccupy themselves with, compared to one of the most harmless diseases out there. Plus I'm pretty sure the current clinical trials are looking at therapeutic treatment and not preventative i.e injecting people who already have Herpes.

There is no record of anybody dying from Herpes alone.

The idea of 'big pharmas' around the world crawling over each other to find a vaccine for HSV-2 is just not true. Genecea and Agenus are biotechs equivalent to that of AHZ compared to Nasdaq standards, and far the multi national pharmas of the world.

A HSV-2 vaccine would be most useful to AIDS sufferers who also have Herpes to minimise the risk of progression, and to sufferers of recurrent shedding who are convinced and or embarrassed by the constant reappearance of signs.

Expand

Just wanted to comment on the incidence of herpes in the USA. I keep quoting from the Ballieu Holst report which I accept may be optomistic but they state that at least 25 million Americans aged 14-49 years are infected.

AHZ Price at posting: 6.9¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

SHN

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

A3D

Defence MOU for propulsion systems pushes Aurora Lab shares higher

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

TIG

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

RAG

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

IMA

Issues emerging as Australian companies tackle critical minerals challenge

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

CXU

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

NWH

NRW Holdings inks $109M deal with BHP for works at Jimblebar

There are more pages in this discussion • 5 more messages in this thread...

First 68 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $11.55		Change -0.130(1.11%)		Mkt cap ! $244.1M

Open	High	Low	Value	Volume
$11.71	$11.89	$11.41	$703.3K	60.2K

Buyers (Bids)

No.	Vol.	Price($)
1	2	$11.55

Sellers (Offers)

Price($)	Vol.	No.
$11.83	500	1

View Market Depth

No.	Vol.	Price($)
1	2	11.550
1	1341	11.500
1	1000	11.400
1	2	11.260
1	8	11.220

Price($)	Vol.	No.
11.830	500	1
11.900	1000	1
12.000	5317	2
12.400	198	1
12.500	429	1

Last trade - 16.10pm 11/10/2024 (20 minute delay)

AVR (ASX) Chart

2:1000000 million chance of getting brain damage from Herpes, page-68

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Defence MOU for propulsion systems pushes Aurora Lab shares higher

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Issues emerging as Australian companies tackle critical minerals challenge

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

2:1000000 million chance of getting brain damage from Herpes, page-68

Top Stories

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

Defence MOU for propulsion systems pushes Aurora Lab shares higher

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Issues emerging as Australian companies tackle critical minerals challenge

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Cauldron Energy reports "excellent" uranium assays in latest drill run

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News